<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805801</url>
  </required_header>
  <id_info>
    <org_study_id>JWP-HEM-401</org_study_id>
    <nct_id>NCT04805801</nct_id>
  </id_info>
  <brief_title>The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors</brief_title>
  <official_title>Observational Study on the Safety of Hemlibra Subcutaneous Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate Safety and efficacy and pharmacokinetics, FVIII Inhibitor titers of Hemlibra&#xD;
      subcutaneous injection (SC inj.) in Korean Hemophilia A patients with/without FVIII&#xD;
      Inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Target subject :&#xD;
&#xD;
        1. Patients with Hemophilia A with FVIII inhibitors&#xD;
&#xD;
        2. Patients with severe Hemophilia A without FVIII inhibitors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2019</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>for 24weeks</time_frame>
    <description>AEs will be described for AEs and Adverse Drug Reactions (ADRs), Adverse Events of Special Interest (AESIs), other important AEs. Severity, outcome, causal relationship with study drug, etc. of AEs will be analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleeding episode Rate (ABR)</measure>
    <time_frame>for 24weeks</time_frame>
    <description>The number of bleeds will be also annualized for each patient using the following formula</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Hemophilia A With Inhibitor</condition>
  <condition>Hemophilia A Without Inhibitor</condition>
  <arm_group>
    <arm_group_label>Hemophilia A with FVIII inhibitors</arm_group_label>
    <description>Hemophilia A patients with FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemophilia A without FVIII inhibitors</arm_group_label>
    <description>Hemophilia A patients without FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emicizumab subcutaneous injection</intervention_name>
    <description>Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.</description>
    <arm_group_label>Hemophilia A with FVIII inhibitors</arm_group_label>
    <arm_group_label>Hemophilia A without FVIII inhibitors</arm_group_label>
    <other_name>Emicizumab concentration, FVIII inhibitor titer, FVIII Activity lab test</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Emicizumab Concentration Factor FVIII Inhibitor FVIII Activity&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1 .Hemophilia A patients with FVIII inhibitors 2. Severe Hemophilia A patients without&#xD;
        FVIII inhibitors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with Hemophilia A (congenital factor VIII deficiency) who will receive&#xD;
             Hemlibra SC inj. according to medical decision by investigator&#xD;
&#xD;
          2. Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are hypersensitive to Emicizumab&#xD;
&#xD;
          2. Subjects who are hypersensitive to mouse or hamster protein&#xD;
&#xD;
          3. Subjects with myocardial infarction or the history who are prohibited from&#xD;
             administering L-Arginine containing drug&#xD;
&#xD;
          4. Subjects who participated in other clinical trials within a month before enrollment&#xD;
             (or the first administration of Hemlibra SC inj.) (Unable to participate in other&#xD;
             clinical trials related to Hemophilia A treatment even after enrollment)&#xD;
&#xD;
          5. Subjects who the investigator deems inappropriate for the study.&#xD;
&#xD;
          6. Moderate/Mild for Hemophilia A patients without FVIII inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuhl Joo Lyu, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chuhl Joo Lyu, Prof</last_name>
    <phone>+82222282060</phone>
    <email>CJ@yuhs.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>YoungShil Park, Prof.</last_name>
    <phone>+8224407174</phone>
    <email>pysmd@khnmc.or.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuhl-Joo Lyu, Prof</last_name>
      <phone>+82222282060</phone>
      <email>CJ@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

